{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:18:18Z","timestamp":1779909498940,"version":"3.53.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006765","name":"Chinese Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.yebeh.2022.108781","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T02:35:04Z","timestamp":1659148504000},"page":"108781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Efficacy and safety of lacosamide in pediatric patients with epilepsy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"134","author":[{"given":"Chunsong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yebeh.2022.108781_b0005","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies [published correction appears in Neurology. 2017;89(6):642]","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108781_b0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108781_b0015","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.yebeh.2022.108781_b0020","doi-asserted-by":"crossref","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Hauser WA, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies [published correction appears in Epilepsia. 2010;51(9):1922]. Epilepsia. 2010;51(6):1069-77.","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"key":"10.1016\/j.yebeh.2022.108781_b0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eplepsyres.2018.03.018","article-title":"The prevalence rates of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy: A systematic review and meta analysis","volume":"142","author":"Yang","year":"2018","journal-title":"Epilepsy Res"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2022.108781_b0030","doi-asserted-by":"crossref","first-page":"106662","DOI":"10.1016\/j.yebeh.2019.106662","article-title":"Prevalence of medication adherence and factors influencing adherence to antiepileptic drugs in children with epilepsy from western China: A cross-sectional survey","volume":"104","author":"Yang","year":"2020","journal-title":"Epilepsy Behavior"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108781_b0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/CON.0000000000000712","article-title":"Antiepileptic drug treatment of epilepsy in children","volume":"25","author":"Moosa","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108781_b0040","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejpn.2019.05.002","article-title":"Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy - A systematic review of the literature using lacosamide as an example","volume":"23","author":"Arzimanoglou","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108781_b0045","doi-asserted-by":"crossref","first-page":"119342","DOI":"10.1016\/j.lfs.2021.119342","article-title":"Pharmacology of lacosamide: From its molecular mechanisms and pharmacokinetics to future therapeutic applications","volume":"275","author":"Carona","year":"2021","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108781_b0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2022.108781_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2014.11.007","article-title":"Lacosamide as adjunctive therapy in refractory epilepsy in adults: a systematic review","volume":"25","author":"Paquette","year":"2015","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108781_b0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40272-018-0286-0","article-title":"A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation","volume":"20","author":"Arzimanoglou","year":"2018","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.yebeh.2022.108781_b0065","doi-asserted-by":"crossref","first-page":"712717","DOI":"10.3389\/fneur.2021.712717","article-title":"Clinical efficacy and safety of lacosamide as an adjunctive treatment in adults with refractory epilepsy","volume":"12","author":"Hou","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2022.108781_b0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review","volume":"56","author":"Ortiz de la Rosa","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108781_b0075","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (editors). Cochrane handbook for systematic reviews of interventions version 6.3(updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org\/handbook."},{"issue":"9","key":"10.1016\/j.yebeh.2022.108781_b0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.yebeh.2022.108781_b0085","unstructured":"Appendix 4 Quality of Case Series Form. National Institute for Health and Care Excellence (NICE). http:\/\/www.nice.org.uk\/guidance\/index. Accessed February 1, 2022."},{"issue":"12","key":"10.1016\/j.yebeh.2022.108781_b0090","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000008126","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"Farkas","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108781_b0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: Comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108781_b0100","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy","volume":"31","author":"Miskin","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108781_b0105","doi-asserted-by":"crossref","first-page":"107814","DOI":"10.1016\/j.yebeh.2021.107814","article-title":"Safety, efficacy, and tolerability of lacosamide for the treatment of epilepsy in pediatric patients in Uygur","volume":"117","author":"Zhao","year":"2021","journal-title":"China Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108781_b0110","first-page":"98","article-title":"Clinical observation on the curative effect of lacosamine in addition treatment of refractory epilepsy in children","volume":"6","author":"Feng","year":"2020","journal-title":"J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108781_b0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.seizure.2020.04.016","article-title":"Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East","volume":"79","author":"Hmaimess","year":"2020","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108781_b0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jpc.14156","article-title":"Lacosamide in children with drug-resistant epilepsy","volume":"55","author":"R\u00fcegger","year":"2019","journal-title":"J Paediatr Child Health"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108781_b0125","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: A single-center observational study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.yebeh.2022.108781_b0130","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00381-017-3586-8","article-title":"Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients","volume":"33","author":"Yildiz","year":"2017","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.yebeh.2022.108781_b0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pediatrneurol.2016.03.021","article-title":"Intravenous lacosamide in pediatric status epilepticus: an open-label efficacy and safety study","volume":"61","author":"Poddar","year":"2016","journal-title":"Pediatr Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108781_b0140","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/jpc.12850","article-title":"Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood","volume":"51","author":"Gulati","year":"2015","journal-title":"J Paediatr Child Health"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108781_b0145","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/epd.2015.0782","article-title":"Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study","volume":"17","author":"Toupin","year":"2015","journal-title":"Epileptic Disord"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108781_b0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ane.12221","article-title":"Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome","volume":"129","author":"Grosso","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108781_b0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108781_b0160","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.eplepsyres.2014.08.021","article-title":"Lacosamide efficacy in epileptic syndromes with continuous spike and waves during slow sleep (CSWS)","volume":"108","author":"Grosso","year":"2014","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108781_b0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pediatrneurol.2014.07.004","article-title":"Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy","volume":"51","author":"Pasha","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108781_b0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy","volume":"29","author":"Yorns","year":"2014","journal-title":"J Child Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108781_b0180","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108781_b0185","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108781_b0190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary efficacy and safety of lacosamide in children with refractory epilepsy","volume":"16","author":"Heyman","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108781_b0195","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yebeh.2011.02.005","article-title":"Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy","volume":"20","author":"Gavatha","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108781_b0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijpp.12371","article-title":"Children\/young people taking long-term medication: a survey of community pharmacists' experiences in England","volume":"26","author":"Aston","year":"2018","journal-title":"Int J Pharm Pract"},{"issue":"22","key":"10.1016\/j.yebeh.2022.108781_b0200","first-page":"2911","article-title":"Long - term efficacy and safety of lacosamine as an adjuvant therapy for patients with partial - onset seizures: A Meta-analysis","volume":"15","author":"Luo","year":"2019","journal-title":"Chin J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108781_b0205","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial","volume":"91","author":"Vossler","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108781_b0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108781_b0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eplepsyres.2016.08.032","article-title":"Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study","volume":"127","author":"Hong","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108781_b0220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.seizure.2021.07.017","article-title":"Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis","volume":"91","author":"Panda","year":"2021","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108781_b0225","doi-asserted-by":"crossref","first-page":"e007711","DOI":"10.1136\/bmjopen-2015-007711","article-title":"Safety of lamotrigine in paediatrics: a systematic review","volume":"5","author":"Egunsola","year":"2015","journal-title":"BMJ open"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108781_b0230","doi-asserted-by":"crossref","first-page":"e0149686","DOI":"10.1371\/journal.pone.0149686","article-title":"Safety of levetiracetam in paediatrics: A systematic review","volume":"11","author":"Egunsola","year":"2016","journal-title":"PLoS ONE"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502200230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502200230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:49:25Z","timestamp":1761504565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502200230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":46,"alternative-id":["S152550502200230X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108781","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lacosamide in pediatric patients with epilepsy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108781"}}